Equities

FitLife Brands Inc

FitLife Brands Inc

Actions
Consumer Staples Food Producers
  • Price (USD)28.99
  • Today's Change1.39 / 5.04%
  • Shares traded2.77k
  • 1 Year change+68.06%
  • Beta0.9573
Data delayed at least 15 minutes, as of May 07 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

FitLife Brands, Inc. is a developer and marketer proprietary nutritional supplements and wellness products for health-conscious consumers. It markets approximately 300 different products primarily online, through domestic and international GNC franchise locations as well as through more than 17,000 additional domestic retail locations. It offers NDS Nutrition, PMD Sports, SirenLabs, Core Active, Nutrology, and Metis Nutrition (together, NDS Products); iSatori, BioGenetic Laboratories, and Energize (together, the iSatori Products); Dr. Tobias, All Natural Advice, and Maritime Naturals (together, the MRC Products) and MusclePharm. Its NDS brand includes premium weight loss, sports nutrition, and general health products. Its PMD brand includes premium sports nutrition products. Its Nutrology brand included sports nutrition and general wellness products with an emphasis on natural, vegan, and organic ingredients. Its SirenLabs brand includes weight loss and sports nutrition products.

  • Revenue in USD (TTM)52.70m
  • Net income in USD5.30m
  • Incorporated2005
  • Employees37.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
FTLF:NAQ since
announced
Transaction
value
MusclePharm CorpDeal completed27 Sep 202327 Sep 2023Deal completed89.73%28.51m
Data delayed at least 15 minutes, as of May 07 2024 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Vor Biopharma Inc0.00-117.86m119.38m168.00--0.7883-----1.75-1.750.002.220.00----0.00-47.38-45.79-50.28-48.98------------0.00-------27.98------
Corvus Pharmaceuticals Inc0.00-27.03m119.47m28.00--2.42-----0.5642-0.56420.000.78890.00----0.00-47.51-38.31-56.21-43.34-----------6.330.00------34.57---37.45--
Immunic Inc0.00-93.61m120.71m77.00--2.09-----2.11-2.110.000.64040.00----0.00-102.84-72.09-129.79-80.11------------0.00------22.25---10.97--
Coya Therapeutics Inc6.00m-7.99m121.78m8.00--3.37--20.29-0.8219-0.82190.59062.470.2417----750,276.30-32.17---39.17-------133.08------0.00------34.77------
Inotiv Inc585.17m-33.21m123.02m1.96k--0.4845.620.2102-1.29-1.2922.739.850.68586.467.12299,320.70-3.96-23.84-4.62-29.2630.2929.31-5.78-33.241.280.14310.5988--4.5285.1068.80--83.64--
Leap Therapeutics Inc0.00-81.41m123.21m54.00--1.37-----5.11-5.110.002.350.00----0.00-113.72-80.06-136.52-95.03-------7,900.37----0.00-------49.12------
Vistagen Therapeutics Inc1.04m-32.07m124.86m37.00--1.01--119.79-3.56-3.560.07754.560.013----31,584.85-39.89-77.80-42.10-85.00-----3,076.62-8,640.25----0.00006---120.50---21.64--165.73--
Omega Therapeutics Inc3.10m-97.43m125.75m93.00--2.17--40.63-1.81-1.810.05731.050.0177--0.917233,279.57-55.62---64.61-------3,147.92------0.2456--49.25--5.13------
Citius Pharmaceuticals Inc0.00-39.33m125.86m22.00--1.31-----0.255-0.2550.000.5330.00----0.00-36.52-30.26-38.61-32.11------------0.00-------0.1589------
FitLife Brands Inc52.70m5.30m126.91m37.0025.534.6923.552.411.081.0810.745.881.303.4438.311,424,297.0013.0726.4015.9433.9240.6742.0910.0517.650.541916.810.4253--82.9725.2819.5867.31----
OptiNose Inc70.99m-35.48m128.86m132.00------1.82-0.3162-0.31620.6329-0.77050.56350.98692.64537,780.30-28.17-48.25---98.9587.8486.96-49.99-131.660.5511-1.792.99---6.9358.6452.58---27.96--
Hongchang International Co Ltd2.68m-378.79k129.76m8.00--3.20--48.49-0.0009-0.00090.00710.0780.1065--2.78---1.51-7.98-1.60-10.942.5911.47-14.16-64.883.74--0.1417--3,289.22---42.63------
Rezolute Inc0.00-56.83m131.22m51.00--1.41-----1.11-1.110.002.310.00----0.00-45.04-58.48-47.75-63.38------------0.00-------26.13--92.29--
DiaMedica Therapeutics Inc0.00-19.38m132.85m18.00--2.60-----0.6168-0.61680.001.350.00----0.00-43.77-45.38-46.37-48.24------------0.00008-------41.72---13.65--
Karyopharm Therapeutics Inc146.03m-143.10m133.94m325.00------0.9172-1.25-1.251.28-1.190.48791.363.94449,332.30-47.81-53.02-61.78-65.8596.6297.18-97.99-125.153.32-10.061.81---7.0336.9313.43------
Data as of May 07 2024. Currency figures normalised to FitLife Brands Inc's reporting currency: US Dollar USD

Institutional shareholders

47.33%Per cent of shares held by top holders
HolderShares% Held
Sudbury Capital Management LLCas of 28 Dec 20232.07m45.06%
Horizon Kinetics Asset Management LLCas of 31 Dec 202377.23k1.68%
Millennium Management LLCas of 31 Dec 202312.85k0.28%
Geode Capital Management LLCas of 31 Dec 202310.33k0.23%
Osaic Wealth, Inc. (Investment Management)as of 31 Dec 20231.60k0.04%
Tower Research Capital LLCas of 31 Dec 20231.00k0.02%
Harbor Investment Advisory LLCas of 31 Mar 2024900.000.02%
UBS Securities LLCas of 31 Dec 202381.000.00%
Wells Fargo Bank, NA (Private Banking)as of 31 Dec 202314.000.00%
JPMorgan Securities LLC (Investment Management)as of 31 Dec 20233.000.00%
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.